Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

The Investment Column: Outlook sours for Tate & Lyle

Andrew Yates
Tuesday 03 February 1998 19:02 EST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Tate & Lyle's profits warning yesterday left a bitter taste in the mouth. The announcement that earnings would be flat for the year to September took the market completely by surprise and sent the shares down 41p to 507p.

To be fair, the group is hardly to blame for the outbreak of a sugar beet disease in Nebraska which wiped out its crops and will knock pounds 12m off the bottom line this year.

However, news of cost overruns in its new pounds 300m starch plant in northern France is of more concern. There were also worrying noises about intense competition in the European and US sweeteners and starch markets.

It is not all bad news. There should an upturn this year at Staley, which makes corn syrup for soft drinks. The annual corn syrup prices are currently being negotiated and the signs are they could show a healthy rise this year. However, US profits could still be flat, with any improvement at Staley offset by problems elsewhere.

That said, investors should take a longer-term view. The group's movement into higher-margin modified starches is well founded. Extensive cost- cutting has meant Staley has been a resilient performer, even during the hard times. And Tate & Lyle's heavy expenditure programme will begin to pay off next year.

Analysts have downgraded profits by pounds 20m to pounds 240m, putting the shares on a prospective price-earnings ratio of 15.

Tate & Lyle's shares have had a strong run in the past few months and yesterday's price fall points to the fact that its rating probably rose too quickly, too soon. After all, Tate & Lyle remains a cyclical business and the pounds 311m profit it made in 1995 is already a distant memory. However, shareholders should hold on to reap benefits of the group's investment.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in